Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

KALA BIO, Inc. - Common Stock (NQ:KALA)

0.1880 -0.0020 (-1.05%)
Delayed Quote Updated: 11:22 AM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about KALA BIO, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
KALA BIO to Present at Jefferies Global Healthcare Conference
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA Stock Earnings: Kala Pharmaceuticals Misses EPS for Q1 2024 ↗
KALA stock results show that Kala Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA Stock Earnings: Kala Pharmaceuticals Beats EPS for Q4 2023 ↗
KALA stock results show that Kala Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
Kala Bio: Q3 Earnings Insights ↗
 
Via Benzinga
News headline image
Kala Pharmaceuticals: Q1 Earnings Insights ↗
Kala Pharmaceuticals (NASDAQ:KALA) reported its Q1 earnings results on Tuesday, May 9, 2023 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
Where Kala Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO to Participate in Upcoming Investor Conferences in August
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
Kala Pharmaceuticals Announces Name Change to KALA BIO
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
10 Short Squeeze Stocks To Watch: Aeglea Biotherapeutics, Toro Corp, AirSculpt, A Company Moves Up 4,166 Positions & More ↗
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for the next huge move. High short interest and steep borrowing costs are among... 
Via Benzinga
News headline image
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
10 Short Squeeze Stocks To Watch: Toro Corp, PaxMedica, Getty Images And More ↗
Potential short squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the next huge move. High-short interest and high-cost to borrow are among the... 
Via Benzinga
News headline image
Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
5 Short Squeeze Stocks To Watch: Getty Images, Bullfrog AI And A New Leader For The Week ↗
Potential short squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the next huge move. High short interest and high cost to borrow are among the... 
Via Benzinga
News headline image
Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
10 Short Squeeze Stocks To Watch: Getty Images, Guardforce AI And 2 Stocks Moving Up Over 1,000 Positions On The Leaderboard ↗
Potential short squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the next huge move. High short interest and high cost to borrow are among the... 
Via Benzinga
News headline image
5 Short Squeeze Stocks To Watch: Getty Images, PaxMedica, A Mental Health Care Company And More ↗
Potential short squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the next huge move. High short interest and high cost to borrow are among the... 
Via Benzinga
News headline image
Kala Pharmaceuticals Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.